
## 2018 April 10th

- Bangkok Hospital
  - Dr. Yotin Chinvarun

In April 10<sup>th</sup> 2018 two FDG PETs were done to check what the response from methylprednisolone is on brain metabolism and functioning (namely does it improve the dementia secondary to multiple sclerosis?).

So Dr. Yotin does an FDG pet on April 10<sup>th</sup>, then IV methylprednisolone is administered for three days (the 12<sup>th</sup>, 13<sup>th</sup>, and 14<sup>th</sup>) and a repeat FDG PET is done on the 17<sup>th</sup> of April.

The methylprednisolone IVs improves brain functioning and metabolism, indicating that it is an autoimmune condition and it further negates the immediately preceding LP test done in Germany on March 13<sup>th</sup> 2018. The LP test in Germany has an over abundance of evidence against it to show that it is a fraudulated test (from other diagnostic tests, to length of time it takes to do the test, to hospital behavior in Charity Hospital) for the sake of criminal malice in medical settings:



The report states a FDG pet was done before and following up after treatment and show improvement of brain metabolism.

FDG PET study shows lesser hypometabolic activity of bilateral posterior parietal lobes, temporal lobes and left occipital lobe than the previous study. The drug response in a clear way indicates that the condition is MS (since methylprednisolone is a strong but temporary immunosuppressant).